Can a new formulation of an endometriosis drug match the standard?

NCT ID NCT07755956

Not yet recruiting Disease control Sponsor: Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial compares HHK001, an investigational version of leuprorelin acetate, to Enantone, an approved treatment for endometriosis. Both contain the same active ingredient, but HHK001 uses an updated formulation. The study will enroll 30 women aged 18-45 with endometriosis, who will receive a single injection of either drug. Researchers will measure how the body absorbs each medicine, monitor side effects, and track changes in pain scores to see if HHK001 offers any advantages.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: leuprorelin acetate (HHK001, an investigational formulation)
What this could lead to: If HHK001 works as well as Enantone but with a better formulation, it could offer a new treatment option for endometriosis with similar benefits and possibly fewer side effects.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply broadly. The drug may not match Enantone's effectiveness or safety, and side effects like hot flashes or bone density changes are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometriosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIOSIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.